What is the FRAX score, how is it calculated, and how does it guide osteoporosis management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FRAX Score: Comprehensive Overview

FRAX is a WHO-developed computer algorithm that calculates the 10-year probability of hip fracture and major osteoporotic fracture (hip, clinical spine, humerus, or wrist) using easily obtainable clinical risk factors, with or without bone mineral density, to guide treatment decisions in osteoporosis management. 1

What FRAX Calculates

FRAX provides two specific outputs:

  • 10-year probability of hip fracture
  • 10-year probability of major osteoporotic fracture (MOF: hip, clinical spine, humerus, or wrist)

The algorithm integrates both fracture risk and mortality risk, making it particularly valuable as it represents lifetime probability at older ages where life expectancy may be less than 10 years 1.

Input Variables for FRAX Calculation

FRAX requires the following 11 clinical risk factors 2, 3:

Demographic factors:

  • Age (40-90 years)
  • Sex
  • Weight and height (to calculate BMI)
  • Country of residence
  • Ethnicity (in US models: White, Black, Hispanic, Asian)

Clinical risk factors (all dichotomous yes/no):

  • Prior fragility fracture (including radiographic vertebral fracture)
  • Parental history of hip fracture
  • Current tobacco smoking
  • Glucocorticoid use (≥5 mg prednisone daily for ≥3 months, current or past)
  • Rheumatoid arthritis
  • Secondary osteoporosis (type 1 diabetes, osteogenesis imperfecta, untreated hyperthyroidism, hypogonadism, premature menopause, chronic malnutrition/malabsorption, chronic liver disease)
  • Alcohol consumption (≥2 units daily)

Optional enhancement:

  • Femoral neck BMD (significantly improves prediction accuracy) 1

How FRAX Guides Management

Treatment Thresholds

Standard intervention thresholds (endorsed by National Osteoporosis Foundation) 3, 4:

  • 10-year hip fracture risk ≥3% → Consider pharmacologic treatment
  • 10-year major osteoporotic fracture risk ≥20% → Consider pharmacologic treatment

Risk Stratification in Glucocorticoid-Induced Osteoporosis

For patients on glucocorticoids, FRAX requires adjustment 5:

  • Multiply FRAX MOF risk by 1.15 if glucocorticoid dose >7.5 mg/day
  • Multiply FRAX hip fracture risk by 1.2 if glucocorticoid dose >7.5 mg/day

Risk categories for adults ≥40 years on glucocorticoids 5:

High fracture risk:

  • FRAX (GC-adjusted) 10-year MOF risk ≥20%
  • FRAX (GC-adjusted) 10-year hip fracture risk ≥3%
  • Prior osteoporotic fracture(s)
  • Hip or spine T-score ≤-2.5

Moderate fracture risk:

  • FRAX (GC-adjusted) 10-year MOF risk 10-19%
  • FRAX (GC-adjusted) 10-year hip fracture risk >1% and <3%

Low fracture risk:

  • FRAX (GC-adjusted) 10-year MOF risk <10%
  • FRAX (GC-adjusted) 10-year hip fracture risk ≤1%

Clinical Application Algorithm

Step 1: Identify candidates for FRAX assessment

  • Postmenopausal women and men ≥50 years
  • Patients with T-scores between -1.0 and -2.5 (osteopenia) 3, 4
  • Patients on long-term glucocorticoids
  • Those with clinical risk factors but no prior fracture

Step 2: Calculate FRAX score

  • Use country-specific calculator (https://www.shef.ac.uk/FRAX/tool.jsp)
  • Include femoral neck BMD when available (improves accuracy)
  • Apply glucocorticoid adjustment if dose >7.5 mg/day

Step 3: Interpret results and act

  • Hip fracture risk ≥3% OR MOF risk ≥20% → Initiate pharmacologic therapy
  • Prior fragility fracture in older adult → Treat regardless of FRAX score 1
  • T-score ≤-2.5 → Treat regardless of FRAX score 3

Key Advantages of FRAX

  • Captures risk beyond BMD alone: Most fractures occur in patients with osteopenia (T-score -1.0 to -2.5), not osteoporosis 1
  • Identifies more at-risk patients: T-score criteria alone miss approximately 75% of men who will fracture 4
  • Country-specific calibration: Accounts for geographic variations in fracture incidence 1
  • Can be used without BMD: Useful in settings where DXA is unavailable 1
  • Validated in both sexes: Applicable to postmenopausal women and men aged 40-90 years 1, 3

Important Limitations and Caveats

FRAX underestimates risk in:

  • Patients with multiple prior fractures (only counts as yes/no)
  • High-dose glucocorticoid users (binary input only)
  • Heavy alcohol users (≥3 units/day not captured)
  • Patients with frequent falls or frailty
  • Type 2 diabetes mellitus
  • Recent fractures (higher imminent risk)

Race-specific concerns 6:

  • US versions use race-specific fracture incidence data
  • May systematically underestimate risk in non-White populations
  • Creates potential for treatment disparities among patients with identical clinical profiles
  • Unclear which calculator to use for multiracial individuals or recent immigrants

Technical limitations 6:

  • Does not incorporate lumbar spine BMD
  • Does not include trabecular bone score
  • Based on cohort data 30-40 years old
  • Mortality estimates not updated since 2004
  • Only validated for untreated patients 7

When FRAX Alone Is Insufficient

Automatically treat without FRAX calculation:

  • Prior hip or vertebral fracture in older adults 1
  • T-score ≤-2.5 at age ≥70 years 8
  • Two or more osteoporotic fractures 8

Use clinical judgment to override FRAX when:

  • High fall risk present
  • Rapid bone loss documented (≥10% at hip/spine over 1 year) 5
  • Multiple risk factors not captured by FRAX
  • Very high imminent fracture risk (recent fracture, very low BMD)

Monitoring and Reassessment

FRAX should be recalculated when:

  • New fractures occur
  • BMD changes significantly
  • New risk factors develop
  • Considering treatment discontinuation

Critical point: FRAX provides absolute fracture probability, which is more clinically meaningful than relative risk and enables equitable treatment decisions across age groups and populations 1.

Related Questions

What is the recommended management for a patient with a FRAX (Fracture Risk Assessment Tool) 10‑year probability of major osteoporotic fracture of 1.9%?
In a 63-year-old woman with a 10-year FRAX major osteoporotic fracture risk of 12.2% and no prior fracture, what is the recommended management?
Should a patient with osteopenia and a FRAX 10‑year major osteoporotic fracture risk of 18.6% and hip fracture risk of 4.8% be started on osteoporosis therapy?
In a postmenopausal woman with a FRAX 10‑year major osteoporotic fracture risk of 8.8% and a hip fracture risk of 0.17% (1 in 6), what is the appropriate management plan?
When should I use the FRAX calculator and what are the treatment thresholds for 10‑year hip and major osteoporotic fracture risk in adults aged 40 years or older?
How can I calculate the total ultraviolet dose for a patient who is 170 cm tall and weighs 70 kg, and determine the highest per‑cm² dose that can be used without causing phototoxicity?
How long should I wait before switching from dofetilide (Tikosyn) to amiodarone?
What antibiotic regimen should be ordered to broaden coverage for a urinary tract infection beyond ceftriaxone?
According to Advanced Cardiovascular Life Support (ACLS) guidelines, what is the first‑line medication for unstable bradycardia and what is its dosing regimen?
For an adult with moderate-to-severe alcohol use disorder who has failed standard therapies and has no history of psychotic disorder, uncontrolled hypertension, cardiac arrhythmia, or severe liver disease, is psychedelic‑assisted treatment (e.g., psilocybin, ibogaine, ayahuasca) appropriate, and what protocol and safety monitoring are recommended?
In an adult patient with normal quantitative glucose‑6‑phosphate dehydrogenase (G6PD) activity, what minimum hemoglobin level is required to safely initiate primaquine (0.25 mg/kg daily for 14 days) for radical cure of Plasmodium vivax or Plasmodium ovale malaria, and how should dosing be adjusted for hemoglobin between 8–10 g/dL?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.